Nieuwscentrum

jan 28, 2020

Philips’ resultaten vierde kwartaal en jaarresultaat 2019


Philips zet EUR 6 miljard om in het vierde kwartaal, met een vergelijkbare omzetgroei van 3%; het resultaat uit doorlopende activiteiten bedroeg EUR 550 miljoen en de gecorrigeerde EBITA-marge nam toe naar 17,9%

Kerncijfers vierde kwartaal

  • De omzet bedroeg EUR 6 miljard, met een groei van de vergelijkbare omzet van 3%
  • De vergelijkbare orderontvangst nam toe met 3%
  • Het resultaat uit doorlopende activiteiten bedroeg EUR 550 miljoen, vergeleken met EUR 723 miljoen in het vierde kwartaal van 2018
  • De gecorrigeerde EBITA-marge verbeterde met 50 basispunten naar 17,9% van de omzet, vergeleken met 17,4% van de omzet in het vierde kwartaal van 2018
  • Het bedrijfsresultaat bedroeg EUR 730 miljoen, vergeleken met EUR 769 miljoen in het vierde kwartaal van 2018
  • WpA uit doorlopende activiteiten (verwaterd) bedroeg EUR 0,61; de gecorrigeerde WpA uit doorlopende activiteiten (verwaterd) nam toe met 9% vergeleken met het vierde kwartaal van 2018, naar EUR 0,83
  • De operationele kasstroom bedroeg EUR 1.271 miljoen, vergeleken met EUR 1.293 miljoen in het vierde kwartaal van 2018; de vrije kasstroom bedroeg EUR 959 miljoen, vergeleken met EUR 1.019 miljoen in het vierde kwartaal van 2018

 

Kerncijfers gehele jaar

  • De omzet steeg naar EUR 19,5 miljard, met een groei van de vergelijkbare omzet van 4%
  • De vergelijkbare orderontvangst nam toe met 3%
  • Het resultaat uit doorlopende activiteiten bedroeg EUR 1.192 miljoen, vergeleken met EUR 1.310 miljoen in 2018
  • De gecorrigeerde EBITA-marge nam toe met 10 basispunten naar 13,2% van de omzet, vergeleken met 13,1% van de omzet in 2018
  • Het bedrijfsresultaat bedroeg EUR 1.644 miljoen, vergeleken met EUR 1.719 miljoen in 2018
  • WpA uit doorlopende activiteiten (verwaterd) bedroeg EUR 1,30; de gecorrigeerde WpA uit doorlopende activiteiten (verwaterd) nam toe met 15% vergeleken met 2018, naar EUR 2,02
  • De operationele kasstroom bedroeg in totaal EUR 2.032 miljoen, vergeleken met EUR 1.780 miljoen in 2018; de vrije kasstroom steeg naar EUR 1.053 miljoen, vergeleken met EUR 984 miljoen in 2018
  • Voorgesteld dividend van EUR 0,85 per aandeel

 

Bedrijfsupdate

  • Philips gaat eigendomsopties voor het bedrijfsonderdeel Domestic Appliances overwegen
  • Roy Jakobs aangesteld als de nieuwe Chief Business Leader van de Connected Care-bedrijfsonderdelen en volgt daarbij Carla Kriwet op, die het bedrijf verlaat

 

Frans van Houten, CEO:

 

“Ik vind het bemoedigend dat de drie bedrijfssegmenten samen voor een vergelijkbare omzetgroei van 4% gezorgd hebben, evenals een verbetering van de gecorrigeerde EBITA-marge van 120 basispunten in het vierde kwartaal. Dit onder uitdagende omstandigheden. Deze prestaties werden deels tenietgedaan door lagere royalty's uit intellectuele eigendomsrechten vergeleken met het vierde kwartaal van 2018, wat leidde tot 3% vergelijkbare omzetgroei en een verbetering van de gecorrigeerde EBITA-marge van 50 basispunten voor de Groep. De vergelijkbare orderontvangst nam verder toe met 3% na een sterke groei van 10% in het vierde kwartaal van 2018.

 

Voor het jaar als geheel zijn wij tevreden met een groei van het bedrijf naar een omzet van EUR 19,5 miljard met 4,5% vergelijkbare omzetgroei. Daarbij hadden wij een vrije kasstroom van meer dan EUR 1 miljard en nam de gecorrigeerde winst per aandeel uit doorlopende activiteiten toe met 15%. Onze verbeterde winstgevendheid van 10 basispunten voor het jaar bleef achter bij ons plan, deels door tegenwind.


Vooruitkijkend naar 2020 blijven wij geopolitieke en economische risico's zien. Wij streven naar 4-6% vergelijkbare omzetgroei en een verbetering van de corrigeerde EBITA-marge van rond de 100 basispunten, waarbij de vaart van de prestatiestijging in de loop van het jaar naar verwachting zal verbeteren.”

Business segment performance

 

In the fourth quarter, all business segments delivered growth and increased profitability.

 

The Diagnosis & Treatment businesses recorded 5% comparable sales growth in the quarter, driven by high-single-digit growth in Image-Guided Therapy and mid-single-digit growth in Ultrasound. Comparable order intake showed a low-single-digit increase on the back of high-single-digit growth in Q4 2018. The order intake growth was driven by double-digit growth in China and Western Europe. The Adjusted EBITA margin increased to 16.3%, mainly due to sales growth, partly offset by investments and tariffs. For the full year, the Diagnosis & Treatment businesses delivered 5% comparable sales growth and an increased Adjusted EBITA margin of 12.7%.

 

The Connected Care businesses delivered 2% comparable sales growth in the quarter, driven by mid-single-digit growth in Monitoring & Analytics. Comparable order intake showed a mid-single-digit increase, driven by double-digit growth in North America and China. The Adjusted EBITA margin increased to 19.4%, mainly due to sales growth and productivity, partly offset by the impact of tariffs. For the full year, the Connected Care businesses delivered 3% comparable sales growth and the Adjusted EBITA margin decreased to 13.2%.

 

The Personal Health businesses delivered comparable sales growth of 4% in the quarter, driven by double-digit growth in Oral Healthcare and mid-single-digit growth in Personal Care. The Adjusted EBITA margin increased to 20.1%, mainly due to sales growth, a positive mix impact and productivity, partly offset by tariffs. For the full year, the Personal Health businesses delivered 5% comparable sales growth and an increase in Adjusted EBITA margin to 16.1%.

 

Philips’ ongoing focus on innovation and strategic partnerships to make the world healthier and more sustainable resulted in the following highlights in the quarter and the full year:

 

  • In 2019, Philips’ products and solutions improved the lives of 1.64 billion people, compared to 1.54 billion in 2018; this includes 194 million people in underserved communities, compared to 175 million in 2018. Additionally, for the seventh consecutive year Philips was ranked on CDP's Climate Change A-list in recognition of its actions to reduce emissions, mitigate climate risks and develop the low-carbon economy. Philips is the first health technology company to have committed to become carbon-neutral in its operations by 2020.
  • Philips entered into several new long-term strategic partnerships, including a 5-year partnership with the Regional Medical Center in South Carolina to provide diagnostic imaging and image-guided therapy solutions to innovate patient care. Philips also announced a 5-year agreement with US-based Inspira Health to standardize patient monitoring and drive innovation in diagnostic imaging and image-guided therapies in order to enhance patient care and improve clinical workflow performance.
  • Driven by Philips’ innovative portfolio of diagnostic imaging, image-guided therapy and patient monitoring solutions, the company continues to win large contracts in China. For example, Philips signed an agreement with the Xi’an International Medical Group to deliver solutions to address clinical and research needs in cardiology, radiation oncology and critical care.
  • Philips continues to set the standard in integrated solutions for image-guided therapy with the expansion of its Azurion platform with FlexArm and the seamless integration of its smart catheters in the platform. The successful launch of Azurion in China and expansion of its smart catheter offering in Europe and Asia contributed to double-digit comparable sales and order intake growth for the Image-Guided Therapy business in 2019.
  • Demonstrating the success of Philips’ telehealth solutions for critical care, US-based Health First achieved significant results by using Philips’ acute telehealth platform. Powered by Philips’ eCareManager, Health First’s VitalWatch eICU achieved a 23% reduction in overall mortality, a 49% reduction in ICU length of stay, and a 35% reduction in length of stay across its four hospitals.
  • Philips expanded its General Care solutions portfolio with the launch of the EarlyVue VS30 in the US. This new vital signs monitor uses automated Early Warning Scoring (EWS) to collect critical vital signs and calculate risk-based alerts that allow clinicians to identify subtle signs of patient deterioration and facilitate communication between caregivers for timely intervention and patient care.
  • Building on the success of Philips’ leading oral care solutions, the company rolled out the BrushSmart program in collaboration with Delta Dental of California, the largest provider of dental benefits in the US. The subscription-based program includes a discounted Sonicare toothbrush, coaching and teledentistry, and connects brushing behaviors at home with professional dental care to better understand, motivate and drive improvements in oral health.
  • The global roll-out of Philips’ premium Shaver S9000 Prestige with BeardAdapt Sensor, which adapts the shaver automatically to the user’s hair, and mid-range Shaver S7000 with a personalized solution for sensitive skin, continues to result in positive user reviews and supported strong performance of the Male Grooming business in the quarter.

 

Domestic Appliances review

 

Philips announced this morning that it will review options for future ownership of the Domestic Appliances business, and start the process of creating a separate legal structure for this business. The Domestic Appliances business is a global leader with EUR 2.3 billion sales in 2019 in kitchen appliances, coffee, garment care and home care appliances.

 

Frans van Houten: “The Domestic Appliances business has significantly contributed to Philips, but it is not a strategic fit for our future as a health technology leader, as we choose to further sharpen our focus along the health continuum and invest in our consumer health and professional healthcare-related businesses.”

 

Executive Committee management changes

 

Roy Jakobs, currently Chief Business Leader of the Personal Health businesses, has been appointed as the new Chief Business Leader of the Connected Care businesses with immediate effect. He succeeds Carla Kriwet, who will leave the company.

 

Frans van Houten: “On behalf of Philips’ Executive Committee, I want to thank Carla for her contributions to Philips, and wish her the best in her future endeavors. At the same time, I am pleased to announce Roy as the new leader of the Connected Care businesses and would like to highlight his global leadership experience, with a strong business performance record, and accomplishments in strategy, digital innovation and new business development in the business-to-consumer and business-to-business domains.”

 

A successor for the Personal Health Chief Business Leader role will be announced in due course. Philips CEO Frans van Houten will lead the Personal Health businesses on an interim basis.

 

Cost savings

 

In the fourth quarter of 2019, cost savings totaled EUR 125 million, with procurement savings of EUR 39 million and savings from overhead and other productivity programs of EUR 86 million, resulting in annual savings of EUR 480 million in 2019.

 

Capital allocation

 

As of the end of the fourth quarter of 2019, Philips has completed 41.5% of its EUR 1.5 billion share buyback program for capital reduction purposes that was announced on January 29, 2019. Further details can be found here.

 

In the quarter, Philips completed the cancellation of 8.5 million shares that were acquired as part of the share buyback program mentioned above.

 

At the end of the fourth quarter of 2019, the total number of issued shares outstanding was 890,973,790 shares, compared to 914,184,087 shares at the end of the fourth quarter of 2018.

 

Regulatory update

 

Philips continues to address the follow-up requests of the US Food and Drug Administration (FDA) as part of its efforts to fulfill its obligations under the Consent Decree [1] and remains in dialogue with the agency.

 

 

[1] Under the Consent Decree, Philips continues to export its range of AED devices and manufacture and distribute its HS1/OnSite/Home automated external defibrillator (AED) model in the US. The company may also continue to service the AEDs provided that certain conditions are met and provide consumables and the relevant accessories.

Report

Fourth Quarter and Annual Results 2019 - Report

Presentation

Fourth Quarter Results 2019 - Results Presentation

Conference call and audio webcast

A conference call with Frans van Houten, CEO, and Abhijit Bhattacharya, CFO, to discuss the results will start at 10:00AM CET, January 28, 2020. A live audio webcast of the conference call will be available through the link below.

Q4 2019 – Fourth quarter and full year 2019 results conference call audio webcast

 

More information about Frans van Houten and Abhijit Bhattacharya

 

Click here for Mr. van Houten's CV and images

Click here for Mr. Bhattacharya's CV and images


Visit our interactive results hub for more on our financial and sustainability performance over the past quarter, including the latest version of our dynamic Lives Improved world map.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 80,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Meer informatieMinder informatie

Forward-looking statements and other important information

 

Forward-looking statements


This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include: statements made about the strategy; estimates of sales growth; future Adjusted EBITA; future restructuring, acquisition-related and other costs; future developments in Philips’ organic business; and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

 

These factors include but are not limited to: changes in industry or market circumstances; economic and political developments; Philips’ increasing focus on health technology; the realization of Philips’ growth ambitions and results in growth geographies; lack of control over certain joint ventures; integration of acquisitions; securing and maintaining Philips’ intellectual property rights and unauthorized use of third-party intellectual property rights; compliance with quality standards, product safety laws and good manufacturing practices; exposure to IT security breaches, IT disruptions, system changes or failures; supply chain management; ability to create new products and solutions; attracting and retaining personnel; financial impacts from Brexit; compliance with regulatory regimes, including data privacy requirements; governmental investigations and legal proceedings with regard to possible anticompetitive market practices and other matters; business conduct rules and regulations; treasury risks and other financial risks; tax risks; costs of defined-benefit pension plans and other postretirement plans; reliability of internal controls, financial reporting and management process. As a result, Philips’ actual future results may differ materially from the plans, goals and expectations set forth in such forward-looking statements. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2018.

 

Third-party market share data

 

Statements regarding market share, including those regarding Philips’ competitive position, contained in this document are based on outside sources such as research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, those statements may also be based on estimates and projections prepared by outside sources or management. Rankings are based on sales unless otherwise stated.

 

Use of non-IFRS information

 

In presenting and discussing the Philips Group’s financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2018.

 

Use of fair value information

 

In presenting the Philips Group’s financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs. Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2018. In certain cases independent valuations are obtained to support management’s determination of fair values.

 

Presentation

 

All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2018, except for IFRS 16 lease accounting, which is implemented per January 1, 2019 and the adoption of IFRIC 23 Uncertainty over Income Tax Treatments effective January 1, 2019, resulting in a balance sheet reclassification. In addition, certain prior-year amounts have been reclassified to conform to the current year presentation.

 

As announced on January 10, 2019, Philips has realigned the composition of its reporting segments effective as of January 1, 2019. The most notable changes are the shifts of the Sleep & Respiratory Care business from the Personal Health segment to the renamed Connected Care segment and most of the Healthcare Informatics business from the renamed Connected Care segment to the Diagnosis & Treatment segment. Accordingly, the comparative figures have been restated. The restatement has been published on the Philips Investor Relations website and can be accessed here.

 

Market Abuse Regulation

 

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Meer informatieMinder informatie

Thema's

Contact

Ben Zwirs

Ben Zwirs

Philips Global Press Office

Tel: +31 6 1521 3446

Martijn van der Starre

Martijn van der Starre

Philips Global Press Office

Tel: +31 6 2847 4617

Business Highlights Q4 2019

Business Highlight:
Philips continues to set the standard in integrated solutions for image-guided therapy with the expansion of its Azurion platform with FlexArm and the seamless integration of its smart catheters in the platform.
Business Highlight
The global roll-out of Philips’ premium Shaver S9000 Prestige with BeardAdapt Sensor and mid-range Shaver S7000 with a personalized solution for sensitive skin supported strong performance of the Male Grooming business in the quarter.
Business Highlights -
Philips expanded its General Care solutions portfolio with the launch of the EarlyVue VS30 in the US.

Delen op sociale media

Gerelateerd nieuws